NeuPath Health (NPTH) Q1 2025 earnings summary

Executive summary

• Achieved record total revenue of $19.3 million for Q1 2025, up 11% year-over-year.

• Adjusted EBITDA reached $1.3 million, a 49% increase year-over-year, marking the 25th consecutive quarter of positive Adjusted EBITDA.

• Strong organic growth in Alberta and Ontario, with improved clinic capacity utilization to 75%.

• New President appointed May 1, 2025, to drive strategic initiatives and growth.

Financial highlights

• Total revenue for Q1 2025 was $19.3 million, compared to $17.5 million in Q1 2024.

• Clinic revenue rose to $18.0 million from $16.2 million year-over-year, driven by fluoroscopy and higher physician reimbursement rates.

• Non-clinic revenue remained stable at $1.3 million.

• Gross margin improved to 18.8% from 18.5% year-over-year.

• Net and comprehensive loss for Q1 2025 was $327,000, slightly improved from $344,000 in Q1 2024.

Outlook and guidance

• Expects continued growth and improved results in 2025, with ongoing evaluation of inorganic growth opportunities.

• Anticipates a potentially material one-time positive payment in Q2 2025 related to prior period physician reimbursements.